Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Transitioning rheumatoid arthritis patients from originator rituximab to biosimilar rituximab (DRL_RI)
2019-002810-37Phase 3Completed
- Sponsor
- Dr. Reddy's Laboratories
- Start
- Jan 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of rituximab in rheumatoid arthritis (RA) (2 arms), sponsored by Dr. Reddy's Laboratories. Primary endpoint: Immunogenicity after transition to DRL_RI versus continued originator rituximab. Started Jan 2020; status: completed.
02
Drugs
rituximab
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on 2019-002810-37.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-002810-37.